#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cancer is a major cause of human death worldwide .
3-1	17-23	Cancer	abstract	new	coref	3-3[4_0]
3-2	24-26	is	_	_	_	_
3-3	27-28	a	abstract[4]	giv[4]	coref	5-5[0_4]
3-4	29-34	major	abstract[4]	giv[4]	_	_
3-5	35-40	cause	abstract[4]	giv[4]	_	_
3-6	41-43	of	abstract[4]	giv[4]	_	_
3-7	44-49	human	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-8	50-55	death	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-9	56-65	worldwide	abstract[4]	giv[4]	_	_
3-10	66-67	.	_	_	_	_

#Text=Most cancer patients receive chemotherapy and radiation therapy , they are often only partially effective and lead to a variety of serious side effects .
4-1	68-72	Most	person[6]	new[6]	coref	5-12[17_6]
4-2	73-79	cancer	person[6]	new[6]	_	_
4-3	80-88	patients	person[6]	new[6]	_	_
4-4	89-96	receive	_	_	_	_
4-5	97-109	chemotherapy	abstract|abstract[8]	new|new[8]	ana|coref|ana|coref	4-10[0_8]|6-3|4-10[0_8]|6-3
4-6	110-113	and	abstract[8]	new[8]	_	_
4-7	114-123	radiation	abstract[8]|abstract|abstract[10]	new[8]|new|new[10]	coref|coref|coref|coref	6-5|6-5[24_10]|6-5|6-5[24_10]
4-8	124-131	therapy	abstract[8]|abstract[10]	new[8]|new[10]	_	_
4-9	132-133	,	_	_	_	_
4-10	134-138	they	abstract	giv	coref	6-3[22_0]
4-11	139-142	are	_	_	_	_
4-12	143-148	often	_	_	_	_
4-13	149-153	only	_	_	_	_
4-14	154-163	partially	_	_	_	_
4-15	164-173	effective	_	_	_	_
4-16	174-177	and	_	_	_	_
4-17	178-182	lead	_	_	_	_
4-18	183-185	to	_	_	_	_
4-19	186-187	a	abstract[12]	new[12]	_	_
4-20	188-195	variety	abstract[12]	new[12]	_	_
4-21	196-198	of	abstract[12]	new[12]	_	_
4-22	199-206	serious	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-23	207-211	side	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-24	212-219	effects	abstract[12]|abstract[13]	new[12]|new[13]	_	_
4-25	220-221	.	_	_	_	_

#Text=In recent decades , cancer immunotherapy has been validated as stimulating patients ’ own immune systems to eliminate cancers .
5-1	222-224	In	_	_	_	_
5-2	225-231	recent	time[14]	new[14]	_	_
5-3	232-239	decades	time[14]	new[14]	_	_
5-4	240-241	,	_	_	_	_
5-5	242-248	cancer	abstract|abstract[16]	giv|new[16]	coref|coref|coref|coref	6-8|6-8[26_16]|6-8|6-8[26_16]
5-6	249-262	immunotherapy	abstract[16]	new[16]	_	_
5-7	263-266	has	_	_	_	_
5-8	267-271	been	_	_	_	_
5-9	272-281	validated	_	_	_	_
5-10	282-284	as	_	_	_	_
5-11	285-296	stimulating	_	_	_	_
5-12	297-305	patients	person[17]|abstract[19]	giv[17]|new[19]	_	_
5-13	306-307	’	person[17]|abstract[19]	giv[17]|new[19]	_	_
5-14	308-311	own	abstract[19]	new[19]	_	_
5-15	312-318	immune	abstract|abstract[19]	new|new[19]	coref	7-41
5-16	319-326	systems	abstract[19]	new[19]	_	_
5-17	327-329	to	_	_	_	_
5-18	330-339	eliminate	_	_	_	_
5-19	340-347	cancers	abstract	new	_	_
5-20	348-349	.	_	_	_	_

#Text=Compared to chemotherapy and radiation therapy , cancer immunotherapy can specifically target tumor cells by modulating immune cells without damage to normal cells .
6-1	350-358	Compared	_	_	_	_
6-2	359-361	to	_	_	_	_
6-3	362-374	chemotherapy	abstract|abstract[22]	giv|giv[22]	_	_
6-4	375-378	and	abstract[22]	giv[22]	_	_
6-5	379-388	radiation	abstract[22]|abstract|abstract[24]	giv[22]|giv|giv[24]	coref|coref	15-10[100_24]|15-10[100_24]
6-6	389-396	therapy	abstract[22]|abstract[24]	giv[22]|giv[24]	_	_
6-7	397-398	,	_	_	_	_
6-8	399-405	cancer	abstract|abstract[26]	giv|giv[26]	coref|coref	7-4|7-4
6-9	406-419	immunotherapy	abstract[26]	giv[26]	_	_
6-10	420-423	can	_	_	_	_
6-11	424-436	specifically	_	_	_	_
6-12	437-443	target	_	_	_	_
6-13	444-449	tumor	abstract|object[28]	new|new[28]	coref|coref	6-17[29_28]|6-17[29_28]
6-14	450-455	cells	object[28]	new[28]	_	_
6-15	456-458	by	_	_	_	_
6-16	459-469	modulating	_	_	_	_
6-17	470-476	immune	object[29]	giv[29]	coref	6-22[31_29]
6-18	477-482	cells	object[29]	giv[29]	_	_
6-19	483-490	without	_	_	_	_
6-20	491-497	damage	abstract[30]	new[30]	_	_
6-21	498-500	to	abstract[30]	new[30]	_	_
6-22	501-507	normal	abstract[30]|object[31]	new[30]|giv[31]	coref	8-10[52_31]
6-23	508-513	cells	abstract[30]|object[31]	new[30]|giv[31]	_	_
6-24	514-515	.	_	_	_	_

#Text=A variety of cancer immunotherapies , including DC-based cancer vaccines , chimeric antigen receptor-T lymphocyte therapies , immune checkpoint blockade antibody therapies , oncolytic vaccine , and cytokines therapies , have been developed to induce tumor-specific and cytotoxic T lymphocyte immune responses .
7-1	516-517	A	abstract[32]	new[32]	_	_
7-2	518-525	variety	abstract[32]	new[32]	_	_
7-3	526-528	of	abstract[32]	new[32]	_	_
7-4	529-535	cancer	abstract[32]|abstract|abstract[34]	new[32]|giv|new[34]	coref|coref	7-9|7-9
7-5	536-551	immunotherapies	abstract[32]|abstract[34]	new[32]|new[34]	_	_
7-6	552-553	,	abstract[32]	new[32]	_	_
7-7	554-563	including	abstract[32]	new[32]	_	_
7-8	564-572	DC-based	abstract[32]|object[36]	new[32]|new[36]	_	_
7-9	573-579	cancer	abstract[32]|abstract|object[36]	new[32]|giv|new[36]	coref	14-14
7-10	580-588	vaccines	abstract[32]|object[36]	new[32]|new[36]	_	_
7-11	589-590	,	abstract[32]	new[32]	_	_
7-12	591-599	chimeric	abstract[32]|substance[37]	new[32]|new[37]	coref	13-7[83_37]
7-13	600-607	antigen	abstract[32]|substance[37]	new[32]|new[37]	_	_
7-14	608-618	receptor-T	abstract[32]	new[32]	_	_
7-15	619-629	lymphocyte	abstract[32]|object[38]	new[32]|new[38]	_	_
7-16	630-639	therapies	abstract[32]|object[38]	new[32]|new[38]	_	_
7-17	640-641	,	abstract[32]	new[32]	_	_
7-18	642-648	immune	abstract[32]|abstract[40]	new[32]|new[40]	_	_
7-19	649-659	checkpoint	abstract[32]|place|abstract[40]	new[32]|new|new[40]	_	_
7-20	660-668	blockade	abstract[32]|abstract[40]	new[32]|new[40]	_	_
7-21	669-677	antibody	abstract[32]|substance|object[42]	new[32]|new|new[42]	_	_
7-22	678-687	therapies	abstract[32]|object[42]	new[32]|new[42]	_	_
7-23	688-689	,	abstract[32]	new[32]	_	_
7-24	690-699	oncolytic	abstract[32]|substance[43]	new[32]|new[43]	coref	12-1[78_43]
7-25	700-707	vaccine	abstract[32]|substance[43]	new[32]|new[43]	_	_
7-26	708-709	,	abstract[32]	new[32]	_	_
7-27	710-713	and	abstract[32]	new[32]	_	_
7-28	714-723	cytokines	abstract[32]|abstract|object[45]	new[32]|new|new[45]	coref|coref|coref|coref	8-4[0_45]|11-13[73_0]|8-4[0_45]|11-13[73_0]
7-29	724-733	therapies	abstract[32]|object[45]	new[32]|new[45]	_	_
7-30	734-735	,	_	_	_	_
7-31	736-740	have	_	_	_	_
7-32	741-745	been	_	_	_	_
7-33	746-755	developed	_	_	_	_
7-34	756-758	to	_	_	_	_
7-35	759-765	induce	_	_	_	_
7-36	766-780	tumor-specific	abstract[49]	new[49]	coref	9-23[61_49]
7-37	781-784	and	abstract[49]	new[49]	_	_
7-38	785-794	cytotoxic	abstract[49]	new[49]	_	_
7-39	795-796	T	person|abstract[49]	new|new[49]	coref	13-31
7-40	797-807	lymphocyte	abstract|abstract[49]	new|new[49]	_	_
7-41	808-814	immune	abstract|abstract[49]	giv|new[49]	coref	9-24
7-42	815-824	responses	abstract[49]	new[49]	_	_
7-43	825-826	.	_	_	_	_

#Text=Dendritic cell based therapies have been widely investigated because dendritic cells ( DCs ) are thought to be the initiator in modulating immunity .
8-1	827-836	Dendritic	object[50]	new[50]	coref	27-8[204_50]
8-2	837-841	cell	object[50]	new[50]	_	_
8-3	842-847	based	_	_	_	_
8-4	848-857	therapies	object	giv	_	_
8-5	858-862	have	_	_	_	_
8-6	863-867	been	_	_	_	_
8-7	868-874	widely	_	_	_	_
8-8	875-887	investigated	_	_	_	_
8-9	888-895	because	_	_	_	_
8-10	896-905	dendritic	object[52]	giv[52]	coref	14-14[94_52]
8-11	906-911	cells	object[52]	giv[52]	_	_
8-12	912-913	(	_	_	_	_
8-13	914-917	DCs	place	new	coref	9-1
8-14	918-919	)	_	_	_	_
8-15	920-923	are	_	_	_	_
8-16	924-931	thought	_	_	_	_
8-17	932-934	to	_	_	_	_
8-18	935-937	be	_	_	_	_
8-19	938-941	the	abstract[54]	new[54]	_	_
8-20	942-951	initiator	abstract[54]	new[54]	_	_
8-21	952-954	in	_	_	_	_
8-22	955-965	modulating	_	_	_	_
8-23	966-974	immunity	abstract	new	coref	18-32[126_0]
8-24	975-976	.	_	_	_	_

#Text=DCs are known as professional antigen-presenting cells , responsible for swallowing tumor-associated antigens , presenting them to T lymphocytes , and inducing antigen-specific immune responses .
9-1	977-980	DCs	place	giv	ana	9-16
9-2	981-984	are	_	_	_	_
9-3	985-990	known	_	_	_	_
9-4	991-993	as	_	_	_	_
9-5	994-1006	professional	_	_	_	_
9-6	1007-1025	antigen-presenting	_	_	_	_
9-7	1026-1031	cells	_	_	_	_
9-8	1032-1033	,	_	_	_	_
9-9	1034-1045	responsible	_	_	_	_
9-10	1046-1049	for	_	_	_	_
9-11	1050-1060	swallowing	_	_	_	_
9-12	1061-1077	tumor-associated	substance[57]	new[57]	coref	10-11[64_57]
9-13	1078-1086	antigens	substance[57]	new[57]	_	_
9-14	1087-1088	,	_	_	_	_
9-15	1089-1099	presenting	_	_	_	_
9-16	1100-1104	them	place	giv	coref	10-2
9-17	1105-1107	to	_	_	_	_
9-18	1108-1109	T	person[59]	new[59]	ana	10-8[0_59]
9-19	1110-1121	lymphocytes	person[59]	new[59]	_	_
9-20	1122-1123	,	_	_	_	_
9-21	1124-1127	and	_	_	_	_
9-22	1128-1136	inducing	_	_	_	_
9-23	1137-1153	antigen-specific	abstract[61]	giv[61]	coref	11-23[77_61]
9-24	1154-1160	immune	abstract|abstract[61]	giv|giv[61]	coref	11-24
9-25	1161-1170	responses	abstract[61]	giv[61]	_	_
9-26	1171-1172	.	_	_	_	_

#Text=When DCs mature and become activated , they will swallow the foreign substances and subsequently present the antigenic epitopes on major histocompatibility complex ( MHC ) molecules .
10-1	1173-1177	When	_	_	_	_
10-2	1178-1181	DCs	place	giv	coref	11-6[70_0]
10-3	1182-1188	mature	_	_	_	_
10-4	1189-1192	and	_	_	_	_
10-5	1193-1199	become	_	_	_	_
10-6	1200-1209	activated	_	_	_	_
10-7	1210-1211	,	_	_	_	_
10-8	1212-1216	they	person	giv	coref	13-31[88_0]
10-9	1217-1221	will	_	_	_	_
10-10	1222-1229	swallow	_	_	_	_
10-11	1230-1233	the	substance[64]	giv[64]	coref	19-23[134_64]
10-12	1234-1241	foreign	substance[64]	giv[64]	_	_
10-13	1242-1252	substances	substance[64]	giv[64]	_	_
10-14	1253-1256	and	_	_	_	_
10-15	1257-1269	subsequently	_	_	_	_
10-16	1270-1277	present	_	_	_	_
10-17	1278-1281	the	object[65]	new[65]	_	_
10-18	1282-1291	antigenic	object[65]	new[65]	_	_
10-19	1292-1300	epitopes	object[65]	new[65]	_	_
10-20	1301-1303	on	_	_	_	_
10-21	1304-1309	major	object[68]	new[68]	_	_
10-22	1310-1328	histocompatibility	abstract|object[68]	new|new[68]	_	_
10-23	1329-1336	complex	object[68]	new[68]	_	_
10-24	1337-1338	(	object[68]	new[68]	_	_
10-25	1339-1342	MHC	object|object[68]	new|new[68]	_	_
10-26	1343-1344	)	object[68]	new[68]	_	_
10-27	1345-1354	molecules	object[68]	new[68]	_	_
10-28	1355-1356	.	_	_	_	_

#Text=At the same time , DCs up-regulate the maturation receptor , release potent cytokines , and migrate into lymph nodes to induce systemic immune responses .
11-1	1357-1359	At	_	_	_	_
11-2	1360-1363	the	time[69]	new[69]	_	_
11-3	1364-1368	same	time[69]	new[69]	_	_
11-4	1369-1373	time	time[69]	new[69]	_	_
11-5	1374-1375	,	_	_	_	_
11-6	1376-1379	DCs	place[70]	giv[70]	coref	12-7[79_70]
11-7	1380-1391	up-regulate	place[70]	giv[70]	_	_
11-8	1392-1395	the	object[72]	new[72]	_	_
11-9	1396-1406	maturation	event|object[72]	new|new[72]	coref	26-39[200_0]
11-10	1407-1415	receptor	object[72]	new[72]	_	_
11-11	1416-1417	,	_	_	_	_
11-12	1418-1425	release	_	_	_	_
11-13	1426-1432	potent	abstract[73]	giv[73]	_	_
11-14	1433-1442	cytokines	abstract[73]	giv[73]	_	_
11-15	1443-1444	,	_	_	_	_
11-16	1445-1448	and	_	_	_	_
11-17	1449-1456	migrate	_	_	_	_
11-18	1457-1461	into	_	_	_	_
11-19	1462-1467	lymph	person|place[75]	new|new[75]	coref|coref|coref|coref	16-11|16-10[103_75]|16-11|16-10[103_75]
11-20	1468-1473	nodes	place[75]	new[75]	_	_
11-21	1474-1476	to	_	_	_	_
11-22	1477-1483	induce	_	_	_	_
11-23	1484-1492	systemic	abstract[77]	giv[77]	coref	16-27[110_77]
11-24	1493-1499	immune	abstract|abstract[77]	giv|giv[77]	coref	14-10
11-25	1500-1509	responses	abstract[77]	giv[77]	_	_
11-26	1510-1511	.	_	_	_	_

#Text=The standard DC-based vaccine begins with first isolating DCs from the patient .
12-1	1512-1515	The	substance[78]	giv[78]	_	_
12-2	1516-1524	standard	substance[78]	giv[78]	_	_
12-3	1525-1533	DC-based	substance[78]	giv[78]	_	_
12-4	1534-1541	vaccine	substance[78]	giv[78]	_	_
12-5	1542-1548	begins	_	_	_	_
12-6	1549-1553	with	_	_	_	_
12-7	1554-1559	first	place[79]	giv[79]	coref	13-3[0_79]
12-8	1560-1569	isolating	place[79]	giv[79]	_	_
12-9	1570-1573	DCs	place[79]	giv[79]	_	_
12-10	1574-1578	from	place[79]	giv[79]	_	_
12-11	1579-1582	the	place[79]|person[80]	giv[79]|new[80]	coref	13-8[82_80]
12-12	1583-1590	patient	place[79]|person[80]	giv[79]|new[80]	_	_
12-13	1591-1592	.	_	_	_	_

#Text=Then , DCs are stimulated with the patient ’s tumor-associated antigen in vitro , and the antigen-stimulated DCs are injected directly back into the patient to induce the activation of T lymphocytes .
13-1	1593-1597	Then	_	_	_	_
13-2	1598-1599	,	_	_	_	_
13-3	1600-1603	DCs	place	giv	coref	13-16[84_0]
13-4	1604-1607	are	_	_	_	_
13-5	1608-1618	stimulated	_	_	_	_
13-6	1619-1623	with	_	_	_	_
13-7	1624-1627	the	substance[83]	giv[83]	_	_
13-8	1628-1635	patient	person[82]|substance[83]	giv[82]|giv[83]	coref	13-24[85_82]
13-9	1636-1638	’s	person[82]|substance[83]	giv[82]|giv[83]	_	_
13-10	1639-1655	tumor-associated	substance[83]	giv[83]	_	_
13-11	1656-1663	antigen	substance[83]	giv[83]	_	_
13-12	1664-1666	in	substance[83]	giv[83]	_	_
13-13	1667-1672	vitro	substance[83]	giv[83]	_	_
13-14	1673-1674	,	_	_	_	_
13-15	1675-1678	and	_	_	_	_
13-16	1679-1682	the	place[84]	giv[84]	coref	16-3[101_84]
13-17	1683-1701	antigen-stimulated	place[84]	giv[84]	_	_
13-18	1702-1705	DCs	place[84]	giv[84]	_	_
13-19	1706-1709	are	_	_	_	_
13-20	1710-1718	injected	_	_	_	_
13-21	1719-1727	directly	_	_	_	_
13-22	1728-1732	back	_	_	_	_
13-23	1733-1737	into	_	_	_	_
13-24	1738-1741	the	person[85]	giv[85]	coref	14-2[89_85]
13-25	1742-1749	patient	person[85]	giv[85]	_	_
13-26	1750-1752	to	_	_	_	_
13-27	1753-1759	induce	_	_	_	_
13-28	1760-1763	the	event[86]	new[86]	_	_
13-29	1764-1774	activation	event[86]	new[86]	_	_
13-30	1775-1777	of	event[86]	new[86]	_	_
13-31	1778-1779	T	event[86]|person|object[88]	new[86]|giv|giv[88]	coref|coref|coref|coref	16-16|16-16[105_88]|16-16|16-16[105_88]
13-32	1780-1791	lymphocytes	event[86]|object[88]	new[86]|giv[88]	_	_
13-33	1792-1793	.	_	_	_	_

#Text=The patient ’s immune system will generate the tumor-specific immune response to destroy cancer cells and prevent cancer recurrence .
14-1	1794-1797	The	abstract[90]	new[90]	coref	18-8[121_90]
14-2	1798-1805	patient	person[89]|abstract[90]	giv[89]|new[90]	_	_
14-3	1806-1808	’s	person[89]|abstract[90]	giv[89]|new[90]	_	_
14-4	1809-1815	immune	abstract[90]	new[90]	_	_
14-5	1816-1822	system	abstract[90]	new[90]	_	_
14-6	1823-1827	will	_	_	_	_
14-7	1828-1836	generate	_	_	_	_
14-8	1837-1840	the	abstract[92]	new[92]	coref	17-17[116_92]
14-9	1841-1855	tumor-specific	abstract[92]	new[92]	_	_
14-10	1856-1862	immune	abstract|abstract[92]	giv|new[92]	coref	16-28
14-11	1863-1871	response	abstract[92]	new[92]	_	_
14-12	1872-1874	to	_	_	_	_
14-13	1875-1882	destroy	_	_	_	_
14-14	1883-1889	cancer	abstract|object[94]	giv|giv[94]	coref|coref|coref|coref	14-18|24-16[176_94]|14-18|24-16[176_94]
14-15	1890-1895	cells	object[94]	giv[94]	_	_
14-16	1896-1899	and	_	_	_	_
14-17	1900-1907	prevent	_	_	_	_
14-18	1908-1914	cancer	abstract|abstract[96]	giv|new[96]	coref|coref	20-10|20-10
14-19	1915-1925	recurrence	abstract[96]	new[96]	_	_
14-20	1926-1927	.	_	_	_	_

#Text=However , several drawbacks restrict the clinical efficacy of DC therapy .
15-1	1928-1935	However	_	_	_	_
15-2	1936-1937	,	_	_	_	_
15-3	1938-1945	several	abstract[97]	new[97]	_	_
15-4	1946-1955	drawbacks	abstract[97]	new[97]	_	_
15-5	1956-1964	restrict	_	_	_	_
15-6	1965-1968	the	abstract[98]	new[98]	_	_
15-7	1969-1977	clinical	abstract[98]	new[98]	_	_
15-8	1978-1986	efficacy	abstract[98]	new[98]	_	_
15-9	1987-1989	of	abstract[98]	new[98]	_	_
15-10	1990-1992	DC	abstract[98]|object|abstract[100]	new[98]|new|giv[100]	_	_
15-11	1993-2000	therapy	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
15-12	2001-2002	.	_	_	_	_

#Text=First , only a few DCs actually migrate to the lymph nodes and interact with T lymphocytes , with the result of a failure to induce antitumor immune responses .
16-1	2003-2008	First	_	_	_	_
16-2	2009-2010	,	_	_	_	_
16-3	2011-2015	only	place[101]	giv[101]	coref	17-9[113_101]
16-4	2016-2017	a	place[101]	giv[101]	_	_
16-5	2018-2021	few	place[101]	giv[101]	_	_
16-6	2022-2025	DCs	place[101]	giv[101]	_	_
16-7	2026-2034	actually	_	_	_	_
16-8	2035-2042	migrate	_	_	_	_
16-9	2043-2045	to	_	_	_	_
16-10	2046-2049	the	place[103]	giv[103]	coref	19-1[128_103]
16-11	2050-2055	lymph	person|place[103]	giv|giv[103]	coref	19-2
16-12	2056-2061	nodes	place[103]	giv[103]	_	_
16-13	2062-2065	and	_	_	_	_
16-14	2066-2074	interact	_	_	_	_
16-15	2075-2079	with	_	_	_	_
16-16	2080-2081	T	person|object[105]	giv|giv[105]	_	_
16-17	2082-2093	lymphocytes	object[105]	giv[105]	_	_
16-18	2094-2095	,	_	_	_	_
16-19	2096-2100	with	_	_	_	_
16-20	2101-2104	the	abstract[106]	new[106]	_	_
16-21	2105-2111	result	abstract[106]	new[106]	_	_
16-22	2112-2114	of	abstract[106]	new[106]	_	_
16-23	2115-2116	a	abstract[106]|abstract[107]	new[106]|new[107]	_	_
16-24	2117-2124	failure	abstract[106]|abstract[107]	new[106]|new[107]	_	_
16-25	2125-2127	to	_	_	_	_
16-26	2128-2134	induce	_	_	_	_
16-27	2135-2144	antitumor	abstract|abstract[110]	new|giv[110]	coref|coref|coref|coref	18-32|19-8[129_110]|18-32|19-8[129_110]
16-28	2145-2151	immune	abstract|abstract[110]	giv|giv[110]	coref	17-19
16-29	2152-2161	responses	abstract[110]	giv[110]	_	_
16-30	2162-2163	.	_	_	_	_

#Text=Moreover , the in vitro culture cannot generate sufficiently powerful DCs , with the result of a weak immune response and limited therapeutic benefit .
17-1	2164-2172	Moreover	_	_	_	_
17-2	2173-2174	,	_	_	_	_
17-3	2175-2178	the	abstract[112]	new[112]	_	_
17-4	2179-2181	in	abstract[112]	new[112]	_	_
17-5	2182-2187	vitro	organization|abstract[112]	new|new[112]	_	_
17-6	2188-2195	culture	abstract[112]	new[112]	_	_
17-7	2196-2202	cannot	_	_	_	_
17-8	2203-2211	generate	_	_	_	_
17-9	2212-2224	sufficiently	place[113]	giv[113]	_	_
17-10	2225-2233	powerful	place[113]	giv[113]	_	_
17-11	2234-2237	DCs	place[113]	giv[113]	_	_
17-12	2238-2239	,	_	_	_	_
17-13	2240-2244	with	_	_	_	_
17-14	2245-2248	the	abstract[114]	new[114]	_	_
17-15	2249-2255	result	abstract[114]	new[114]	_	_
17-16	2256-2258	of	abstract[114]	new[114]	_	_
17-17	2259-2260	a	abstract[114]|abstract[116]	new[114]|giv[116]	coref	18-25[124_116]
17-18	2261-2265	weak	abstract[114]|abstract[116]	new[114]|giv[116]	_	_
17-19	2266-2272	immune	abstract[114]|abstract|abstract[116]	new[114]|giv|giv[116]	coref	19-42
17-20	2273-2281	response	abstract[114]|abstract[116]	new[114]|giv[116]	_	_
17-21	2282-2285	and	abstract[114]	new[114]	_	_
17-22	2286-2293	limited	abstract[114]|abstract[117]	new[114]|new[117]	_	_
17-23	2294-2305	therapeutic	abstract[114]|abstract[117]	new[114]|new[117]	_	_
17-24	2306-2313	benefit	abstract[114]|abstract[117]	new[114]|new[117]	_	_
17-25	2314-2315	.	_	_	_	_

#Text=Thus , it is important to establish an in vitro culturing system or an in vivo DC delivery system that can more reliably induce the immune response and more potently deliver antitumor immunity .
18-1	2316-2320	Thus	_	_	_	_
18-2	2321-2322	,	_	_	_	_
18-3	2323-2325	it	abstract	new	cata	18-3[0_119]
18-4	2326-2328	is	_	_	_	_
18-5	2329-2338	important	_	_	_	_
18-6	2339-2341	to	abstract[119]	new[119]	_	_
18-7	2342-2351	establish	abstract[119]	new[119]	_	_
18-8	2352-2354	an	abstract[121]	giv[121]	_	_
18-9	2355-2357	in	abstract[121]	giv[121]	_	_
18-10	2358-2363	vitro	abstract[121]	giv[121]	_	_
18-11	2364-2373	culturing	abstract|abstract[121]	new|giv[121]	_	_
18-12	2374-2380	system	abstract[121]	giv[121]	_	_
18-13	2381-2383	or	abstract[121]	giv[121]	_	_
18-14	2384-2386	an	abstract[121]	giv[121]	_	_
18-15	2387-2389	in	abstract[121]	giv[121]	_	_
18-16	2390-2394	vivo	abstract[121]	giv[121]	_	_
18-17	2395-2397	DC	abstract[121]|person	giv[121]|new	coref	26-36
18-18	2398-2406	delivery	abstract[121]|abstract	giv[121]|new	_	_
18-19	2407-2413	system	abstract[121]	giv[121]	_	_
18-20	2414-2418	that	_	_	_	_
18-21	2419-2422	can	_	_	_	_
18-22	2423-2427	more	_	_	_	_
18-23	2428-2436	reliably	_	_	_	_
18-24	2437-2443	induce	_	_	_	_
18-25	2444-2447	the	abstract[124]	giv[124]	coref	19-39[140_124]
18-26	2448-2454	immune	abstract[124]	giv[124]	_	_
18-27	2455-2463	response	abstract[124]	giv[124]	_	_
18-28	2464-2467	and	_	_	_	_
18-29	2468-2472	more	_	_	_	_
18-30	2473-2481	potently	_	_	_	_
18-31	2482-2489	deliver	_	_	_	_
18-32	2490-2499	antitumor	abstract|abstract[126]	giv|giv[126]	coref|coref|coref|coref	25-31[184_126]|25-35|25-31[184_126]|25-35
18-33	2500-2508	immunity	abstract[126]	giv[126]	_	_
18-34	2509-2510	.	_	_	_	_

#Text=The lymph nodes are extremely critical in responses to pathogens or danger signals , and their major functions are to filter out deleterious substances by their unique mesh microstructure , to maintain matured immunocytes , and to initiate the antigen-specific adaptive immune response .
19-1	2511-2514	The	place[128]	giv[128]	ana	19-16[0_128]
19-2	2515-2520	lymph	person|place[128]	giv|giv[128]	coref	20-2
19-3	2521-2526	nodes	place[128]	giv[128]	_	_
19-4	2527-2530	are	_	_	_	_
19-5	2531-2540	extremely	_	_	_	_
19-6	2541-2549	critical	_	_	_	_
19-7	2550-2552	in	_	_	_	_
19-8	2553-2562	responses	abstract[129]	giv[129]	_	_
19-9	2563-2565	to	abstract[129]	giv[129]	_	_
19-10	2566-2575	pathogens	abstract[129]|abstract	giv[129]|new	_	_
19-11	2576-2578	or	abstract[129]	giv[129]	_	_
19-12	2579-2585	danger	abstract[129]|abstract[131]	giv[129]|new[131]	_	_
19-13	2586-2593	signals	abstract[129]|abstract[131]	giv[129]|new[131]	_	_
19-14	2594-2595	,	_	_	_	_
19-15	2596-2599	and	_	_	_	_
19-16	2600-2605	their	place|abstract[133]	giv|new[133]	ana|ana	19-26|19-26
19-17	2606-2611	major	abstract[133]	new[133]	_	_
19-18	2612-2621	functions	abstract[133]	new[133]	_	_
19-19	2622-2625	are	_	_	_	_
19-20	2626-2628	to	_	_	_	_
19-21	2629-2635	filter	_	_	_	_
19-22	2636-2639	out	_	_	_	_
19-23	2640-2651	deleterious	substance[134]	giv[134]	_	_
19-24	2652-2662	substances	substance[134]	giv[134]	_	_
19-25	2663-2665	by	substance[134]	giv[134]	_	_
19-26	2666-2671	their	substance[134]|place|object[137]	giv[134]|giv|new[137]	coref|coref|coref|coref	20-1[142_0]|26-20[194_137]|20-1[142_0]|26-20[194_137]
19-27	2672-2678	unique	substance[134]|object[137]	giv[134]|new[137]	_	_
19-28	2679-2683	mesh	substance[134]|object|object[137]	giv[134]|new|new[137]	_	_
19-29	2684-2698	microstructure	substance[134]|object[137]	giv[134]|new[137]	_	_
19-30	2699-2700	,	_	_	_	_
19-31	2701-2703	to	_	_	_	_
19-32	2704-2712	maintain	_	_	_	_
19-33	2713-2720	matured	object[138]	new[138]	_	_
19-34	2721-2732	immunocytes	object[138]	new[138]	_	_
19-35	2733-2734	,	_	_	_	_
19-36	2735-2738	and	_	_	_	_
19-37	2739-2741	to	_	_	_	_
19-38	2742-2750	initiate	_	_	_	_
19-39	2751-2754	the	abstract[140]	giv[140]	coref	25-34[187_140]
19-40	2755-2771	antigen-specific	abstract[140]	giv[140]	_	_
19-41	2772-2780	adaptive	abstract[140]	giv[140]	_	_
19-42	2781-2787	immune	abstract|abstract[140]	giv|giv[140]	coref	25-36
19-43	2788-2796	response	abstract[140]	giv[140]	_	_
19-44	2797-2798	.	_	_	_	_

#Text=The lymph nodes might lose their function because of cancer , obstruction , or infection ; in such cases , surgical resection of lymph nodes is usually indicated .
20-1	2799-2802	The	place[142]	giv[142]	ana	20-6[0_142]
20-2	2803-2808	lymph	person|place[142]	giv|giv[142]	coref	20-24
20-3	2809-2814	nodes	place[142]	giv[142]	_	_
20-4	2815-2820	might	_	_	_	_
20-5	2821-2825	lose	_	_	_	_
20-6	2826-2831	their	place|abstract[144]	giv|new[144]	coref|coref|coref|coref	20-24[151_0]|24-19[177_144]|20-24[151_0]|24-19[177_144]
20-7	2832-2840	function	abstract[144]	new[144]	_	_
20-8	2841-2848	because	abstract[144]	new[144]	_	_
20-9	2849-2851	of	abstract[144]	new[144]	_	_
20-10	2852-2858	cancer	abstract[144]|abstract	new[144]|giv	coref	21-20
20-11	2859-2860	,	abstract[144]	new[144]	_	_
20-12	2861-2872	obstruction	abstract[144]|object	new[144]|new	_	_
20-13	2873-2874	,	abstract[144]	new[144]	_	_
20-14	2875-2877	or	abstract[144]	new[144]	_	_
20-15	2878-2887	infection	abstract[144]|event	new[144]|new	coref	21-16[157_0]
20-16	2888-2889	;	_	_	_	_
20-17	2890-2892	in	_	_	_	_
20-18	2893-2897	such	abstract[148]	new[148]	_	_
20-19	2898-2903	cases	abstract[148]	new[148]	_	_
20-20	2904-2905	,	_	_	_	_
20-21	2906-2914	surgical	event[149]	new[149]	coref	21-3[154_149]
20-22	2915-2924	resection	event[149]	new[149]	_	_
20-23	2925-2927	of	event[149]	new[149]	_	_
20-24	2928-2933	lymph	event[149]|person|place[151]	new[149]|giv|giv[151]	coref|coref	21-3|21-3
20-25	2934-2939	nodes	event[149]|place[151]	new[149]|giv[151]	_	_
20-26	2940-2942	is	_	_	_	_
20-27	2943-2950	usually	_	_	_	_
20-28	2951-2960	indicated	_	_	_	_
20-29	2961-2962	.	_	_	_	_

#Text=However , lymph node resection often causes a wide range of other problems such as increased infection , impaired cancer surveillance , and lymphedema .
21-1	2963-2970	However	_	_	_	_
21-2	2971-2972	,	_	_	_	_
21-3	2973-2978	lymph	person|event[154]	giv|giv[154]	coref|coref	22-8|22-8
21-4	2979-2983	node	object|event[154]	new|giv[154]	coref	22-9
21-5	2984-2993	resection	event[154]	giv[154]	_	_
21-6	2994-2999	often	_	_	_	_
21-7	3000-3006	causes	_	_	_	_
21-8	3007-3008	a	abstract[155]	new[155]	_	_
21-9	3009-3013	wide	abstract[155]	new[155]	_	_
21-10	3014-3019	range	abstract[155]	new[155]	_	_
21-11	3020-3022	of	abstract[155]	new[155]	_	_
21-12	3023-3028	other	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-13	3029-3037	problems	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-14	3038-3042	such	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-15	3043-3045	as	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-16	3046-3055	increased	abstract[155]|abstract[156]|event[157]	new[155]|new[156]|giv[157]	_	_
21-17	3056-3065	infection	abstract[155]|abstract[156]|event[157]	new[155]|new[156]|giv[157]	_	_
21-18	3066-3067	,	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-19	3068-3076	impaired	abstract[155]|abstract[156]|abstract[159]	new[155]|new[156]|new[159]	_	_
21-20	3077-3083	cancer	abstract[155]|abstract[156]|abstract|abstract[159]	new[155]|new[156]|giv|new[159]	_	_
21-21	3084-3096	surveillance	abstract[155]|abstract[156]|abstract[159]	new[155]|new[156]|new[159]	_	_
21-22	3097-3098	,	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-23	3099-3102	and	abstract[155]|abstract[156]	new[155]|new[156]	_	_
21-24	3103-3113	lymphedema	abstract[155]|abstract[156]|abstract	new[155]|new[156]|new	_	_
21-25	3114-3115	.	_	_	_	_

#Text=Consequently , a promising technique for functional lymph node restoration is urgently needed .
22-1	3116-3128	Consequently	_	_	_	_
22-2	3129-3130	,	_	_	_	_
22-3	3131-3132	a	abstract[161]	new[161]	_	_
22-4	3133-3142	promising	abstract[161]	new[161]	_	_
22-5	3143-3152	technique	abstract[161]	new[161]	_	_
22-6	3153-3156	for	abstract[161]	new[161]	_	_
22-7	3157-3167	functional	abstract[161]|event[164]	new[161]|new[164]	_	_
22-8	3168-3173	lymph	abstract[161]|animal|event[164]	new[161]|giv|new[164]	coref	24-9
22-9	3174-3178	node	abstract[161]|object|event[164]	new[161]|giv|new[164]	coref	24-10
22-10	3179-3190	restoration	abstract[161]|event[164]	new[161]|new[164]	_	_
22-11	3191-3193	is	_	_	_	_
22-12	3194-3202	urgently	_	_	_	_
22-13	3203-3209	needed	_	_	_	_
22-14	3210-3211	.	_	_	_	_

#Text=Decellularization has emerged as a process for producing a natural extracellular matrix ( ECM ) , which preserves the intrinsic biological cues and architectural structure of the original tissue .
23-1	3212-3229	Decellularization	abstract	new	_	_
23-2	3230-3233	has	_	_	_	_
23-3	3234-3241	emerged	_	_	_	_
23-4	3242-3244	as	_	_	_	_
23-5	3245-3246	a	_	_	_	_
23-6	3247-3254	process	_	_	_	_
23-7	3255-3258	for	_	_	_	_
23-8	3259-3268	producing	_	_	_	_
23-9	3269-3270	a	object[166]	new[166]	appos	23-14[0_166]
23-10	3271-3278	natural	object[166]	new[166]	_	_
23-11	3279-3292	extracellular	object[166]	new[166]	_	_
23-12	3293-3299	matrix	object[166]	new[166]	_	_
23-13	3300-3301	(	_	_	_	_
23-14	3302-3305	ECM	object	giv	coref	25-10[179_0]
23-15	3306-3307	)	_	_	_	_
23-16	3308-3309	,	_	_	_	_
23-17	3310-3315	which	_	_	_	_
23-18	3316-3325	preserves	_	_	_	_
23-19	3326-3329	the	abstract[168]	new[168]	_	_
23-20	3330-3339	intrinsic	abstract[168]	new[168]	_	_
23-21	3340-3350	biological	abstract[168]	new[168]	_	_
23-22	3351-3355	cues	abstract[168]	new[168]	_	_
23-23	3356-3359	and	_	_	_	_
23-24	3360-3373	architectural	abstract[169]	new[169]	ana	24-1[0_169]
23-25	3374-3383	structure	abstract[169]	new[169]	_	_
23-26	3384-3386	of	abstract[169]	new[169]	_	_
23-27	3387-3390	the	abstract[169]|object[170]	new[169]|new[170]	_	_
23-28	3391-3399	original	abstract[169]|object[170]	new[169]|new[170]	_	_
23-29	3400-3406	tissue	abstract[169]|object[170]	new[169]|new[170]	_	_
23-30	3407-3408	.	_	_	_	_

#Text=It provides a strategy by which to fabricate lymph node scaffolds on which to grow immune cells with immunological function .
24-1	3409-3411	It	abstract	giv	_	_
24-2	3412-3420	provides	_	_	_	_
24-3	3421-3422	a	abstract[172]	new[172]	_	_
24-4	3423-3431	strategy	abstract[172]	new[172]	_	_
24-5	3432-3434	by	_	_	_	_
24-6	3435-3440	which	_	_	_	_
24-7	3441-3443	to	_	_	_	_
24-8	3444-3453	fabricate	_	_	_	_
24-9	3454-3459	lymph	person|object[175]	giv|new[175]	coref|coref|coref|coref	25-22[182_175]|26-12|25-22[182_175]|26-12
24-10	3460-3464	node	abstract|object[175]	giv|new[175]	coref	26-13
24-11	3465-3474	scaffolds	object[175]	new[175]	_	_
24-12	3475-3477	on	_	_	_	_
24-13	3478-3483	which	_	_	_	_
24-14	3484-3486	to	_	_	_	_
24-15	3487-3491	grow	_	_	_	_
24-16	3492-3498	immune	object[176]	giv[176]	coref	25-15[180_176]
24-17	3499-3504	cells	object[176]	giv[176]	_	_
24-18	3505-3509	with	_	_	_	_
24-19	3510-3523	immunological	abstract[177]	giv[177]	_	_
24-20	3524-3532	function	abstract[177]	giv[177]	_	_
24-21	3533-3534	.	_	_	_	_

#Text=Previous studies demonstrated that spleen-derived decellularized ECM or lymph node-associated decellularized ECM can deliver immune cells and promote the organization of lymphoid-like scaffolds ; however , whether these can induce antigen-specific immunity or the antitumor immune response is still unknown .
25-1	3535-3543	Previous	abstract[178]	new[178]	ana	25-28[0_178]
25-2	3544-3551	studies	abstract[178]	new[178]	_	_
25-3	3552-3564	demonstrated	_	_	_	_
25-4	3565-3569	that	_	_	_	_
25-5	3570-3584	spleen-derived	_	_	_	_
25-6	3585-3599	decellularized	_	_	_	_
25-7	3600-3603	ECM	_	_	_	_
25-8	3604-3606	or	_	_	_	_
25-9	3607-3612	lymph	_	_	_	_
25-10	3613-3628	node-associated	object[179]	giv[179]	coref	26-24[0_179]
25-11	3629-3643	decellularized	object[179]	giv[179]	_	_
25-12	3644-3647	ECM	object[179]	giv[179]	_	_
25-13	3648-3651	can	_	_	_	_
25-14	3652-3659	deliver	_	_	_	_
25-15	3660-3666	immune	object[180]	giv[180]	_	_
25-16	3667-3672	cells	object[180]	giv[180]	_	_
25-17	3673-3676	and	_	_	_	_
25-18	3677-3684	promote	_	_	_	_
25-19	3685-3688	the	event[181]	new[181]	_	_
25-20	3689-3701	organization	event[181]	new[181]	_	_
25-21	3702-3704	of	event[181]	new[181]	_	_
25-22	3705-3718	lymphoid-like	event[181]|object[182]	new[181]|giv[182]	_	_
25-23	3719-3728	scaffolds	event[181]|object[182]	new[181]|giv[182]	_	_
25-24	3729-3730	;	_	_	_	_
25-25	3731-3738	however	_	_	_	_
25-26	3739-3740	,	_	_	_	_
25-27	3741-3748	whether	_	_	_	_
25-28	3749-3754	these	abstract	giv	_	_
25-29	3755-3758	can	_	_	_	_
25-30	3759-3765	induce	_	_	_	_
25-31	3766-3782	antigen-specific	abstract[184]	giv[184]	_	_
25-32	3783-3791	immunity	abstract[184]	giv[184]	_	_
25-33	3792-3794	or	_	_	_	_
25-34	3795-3798	the	abstract[187]	giv[187]	coref	27-17[207_187]
25-35	3799-3808	antitumor	abstract|abstract[187]	giv|giv[187]	_	_
25-36	3809-3815	immune	abstract|abstract[187]	giv|giv[187]	coref	27-20
25-37	3816-3824	response	abstract[187]	giv[187]	_	_
25-38	3825-3827	is	_	_	_	_
25-39	3828-3833	still	_	_	_	_
25-40	3834-3841	unknown	_	_	_	_
25-41	3842-3843	.	_	_	_	_

#Text=The aim of this study was to establish a natural decellularized lymph node scaffold ( dLN ) , with preserved original microstructure and ECM , and to validate the ability of the dLN to support DC proliferation and maturation in vitro .
26-1	3844-3847	The	abstract[188]	new[188]	_	_
26-2	3848-3851	aim	abstract[188]	new[188]	_	_
26-3	3852-3854	of	abstract[188]	new[188]	_	_
26-4	3855-3859	this	abstract[188]|event[189]	new[188]|new[189]	coref	27-1[201_189]
26-5	3860-3865	study	abstract[188]|event[189]	new[188]|new[189]	_	_
26-6	3866-3869	was	_	_	_	_
26-7	3870-3872	to	_	_	_	_
26-8	3873-3882	establish	_	_	_	_
26-9	3883-3884	a	object[192]	new[192]	appos	26-16[0_192]
26-10	3885-3892	natural	object[192]	new[192]	_	_
26-11	3893-3907	decellularized	object[192]	new[192]	_	_
26-12	3908-3913	lymph	person|object[192]	giv|new[192]	_	_
26-13	3914-3918	node	abstract|object[192]	giv|new[192]	_	_
26-14	3919-3927	scaffold	object[192]	new[192]	_	_
26-15	3928-3929	(	_	_	_	_
26-16	3930-3933	dLN	object	giv	coref	26-32[197_0]
26-17	3934-3935	)	_	_	_	_
26-18	3936-3937	,	_	_	_	_
26-19	3938-3942	with	_	_	_	_
26-20	3943-3952	preserved	object[194]	giv[194]	_	_
26-21	3953-3961	original	object[194]	giv[194]	_	_
26-22	3962-3976	microstructure	object[194]	giv[194]	_	_
26-23	3977-3980	and	_	_	_	_
26-24	3981-3984	ECM	object	giv	_	_
26-25	3985-3986	,	_	_	_	_
26-26	3987-3990	and	_	_	_	_
26-27	3991-3993	to	_	_	_	_
26-28	3994-4002	validate	_	_	_	_
26-29	4003-4006	the	abstract[196]	new[196]	_	_
26-30	4007-4014	ability	abstract[196]	new[196]	_	_
26-31	4015-4017	of	abstract[196]	new[196]	_	_
26-32	4018-4021	the	abstract[196]|object[197]	new[196]|giv[197]	_	_
26-33	4022-4025	dLN	abstract[196]|object[197]	new[196]|giv[197]	_	_
26-34	4026-4028	to	_	_	_	_
26-35	4029-4036	support	_	_	_	_
26-36	4037-4039	DC	person|abstract[199]	giv|new[199]	_	_
26-37	4040-4053	proliferation	abstract[199]	new[199]	_	_
26-38	4054-4057	and	_	_	_	_
26-39	4058-4068	maturation	event[200]	giv[200]	_	_
26-40	4069-4071	in	event[200]	giv[200]	_	_
26-41	4072-4077	vitro	event[200]	giv[200]	_	_
26-42	4078-4079	.	_	_	_	_

#Text=The study also aimed to verify whether a bone marrow dendritic cell ( BMDC)-dLN can activate a specific antitumor immune response in vivo .
27-1	4080-4083	The	event[201]	giv[201]	_	_
27-2	4084-4089	study	event[201]	giv[201]	_	_
27-3	4090-4094	also	_	_	_	_
27-4	4095-4100	aimed	_	_	_	_
27-5	4101-4103	to	_	_	_	_
27-6	4104-4110	verify	_	_	_	_
27-7	4111-4118	whether	_	_	_	_
27-8	4119-4120	a	object[204]	giv[204]	appos	27-14[0_204]
27-9	4121-4125	bone	object|object[204]	new|giv[204]	_	_
27-10	4126-4132	marrow	animal|object[204]	new|giv[204]	_	_
27-11	4133-4142	dendritic	object[204]	giv[204]	_	_
27-12	4143-4147	cell	object[204]	giv[204]	_	_
27-13	4148-4149	(	_	_	_	_
27-14	4150-4159	BMDC)-dLN	object	giv	_	_
27-15	4160-4163	can	_	_	_	_
27-16	4164-4172	activate	_	_	_	_
27-17	4173-4174	a	abstract[207]	giv[207]	_	_
27-18	4175-4183	specific	abstract[207]	giv[207]	_	_
27-19	4184-4193	antitumor	abstract[207]	giv[207]	_	_
27-20	4194-4200	immune	abstract|abstract[207]	giv|giv[207]	_	_
27-21	4201-4209	response	abstract[207]	giv[207]	_	_
27-22	4210-4212	in	abstract[207]	giv[207]	_	_
27-23	4213-4217	vivo	abstract[207]	giv[207]	_	_
27-24	4218-4219	.	_	_	_	_
